Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation

Autor: Schmidt, Hartmut, Wixner, Jonas, Planté-Bordeneuve, Violaine, Muñoz-Beamud, Francisco, Lladó, Laura, Gillmore, Julian D., Mazzeo, Anna, Li, Xingyu, Arum, Seth, Jay, Patrick Y., Adams, David, Langestroer, Christel, Huesing-Kabar, Anna, Schilling, Matthias, Kabar, Iyad, Backlund, Rolf, Anan, Intissar, Nordh, Erik, Uneus, Erika, Pilebro, Björn, Englund, Ulrika, Coelho, Teresa, Novais, Marta, Perez, Javier, Martins da Silva, Ana, Pesseguerio Miranda, Helena, Ramalho, Joana, Monte, Raquel, Alves, Cristina, Cardaso, Ines, Guimaraes, Nádia, Gentile, Luca, Russo, Massimo, Di Bella, Gianluca, Gaouar, Amina, Cauquil-Michon, Cécile, Kounis, Ilias, Echaniz-Laguna, Andoni, Stéphant, Maëva, Rakotondratafika, Fetra, Boubrit, Yasmine, Labeyrie, Celine, Focsenaunu, Cecile, Le Corvoisier, Phillippe, Ayache, Samar S., Gendre, Thierry, Vervoitte, Laetitia, Arrouasse, Raphaele, Gragera Martinez, Alvaro, Borrachero, Cristina, Manovel, Ana, Diaz Rodriguez, Eusebio, Gutiérrez Gándara, Marta, Fabra Jiménez, Elena, Valentina Vélez Santamaría, Patricia, Martínez Vilar, Yurema, Cachero, Alba, Rannigan, Lisa, Fontana, Marianna, Orrell, Richard, Louth, Sarah, Chacko, Liza, Varughese, Sindhu, Throburn, Douglas, Cohen, Oliver, Law, Steven, Smit, Angelique, Strehina, Svetla

Publikováno v: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 22(6)

Hereditary transthyretin-mediated (hATTR) amyloidosis, or ATTRv amyloidosis, is a progressive disease, for which liver transplantation (LT) has been a long-standing treatment. However, disease progression continues post-LT. This Phase 3b, open-label

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b4b65bec1570c5c2e46378fc54a2e76
https://pubmed.ncbi.nlm.nih.gov/35213769